Drugs / Arbaclofen Placarbil
Arbaclofen Placarbil
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 26 trials · 1 missed | ||||||
| Phase 2 | NCT02511886 | Sep 2015 → Jan 2016 | alcohol-related disorders | Indivior Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00978016 | Sep 2009 → Dec 2010 | gastroesophageal reflux disease | XenoPort, Inc. | Completed | Missed primary |
| Phase 2 | NCT00817986 | Dec 2008 → Jul 2009 | — | XenoPort, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00557973 | Dec 2007 → Apr 2009 | — | XenoPort, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00557401 | Nov 2007 → Sep 2008 | gastroesophageal reflux disease | XenoPort, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00838396 | Oct 2005 → Aug 2006 | gastroesophageal reflux disease | Indivior Inc. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT03058237 Comparator | Jan → Jul 2017 | — | Indivior Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01359566 Comparator | May 2011 → Feb 2013 | multiple sclerosis | XenoPort, Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | arbaclofen placarbil | “The purpose of the study is to evaluate the efficacy and safety of arbaclofen placarbil (XP19986) compared to placebo in patients with gastroesophageal reflux disease.” NCT00838396 ↗ |
| Known as | Arbaclofene placarbil | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107312 ↗ |
| Known as | Arbaclofeno placarbilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107312 ↗ |
| Known as | XP19986 | “The purpose of the study is to evaluate the efficacy and safety of arbaclofen placarbil (XP19986) compared to placebo in patients with gastroesophageal reflux disease.” NCT00838396 ↗ |
| Known as | XP19986 SR1 | “This is a multiple-dose, randomized, placebo-controlled crossover study of the efficacy and safety of XP19986 SR1 in subjects with spasticity due to spinal cord injury.” NCT00557973 ↗ |
| Known as | XP19986 SR3 | “XP19986 SR3, 20 mg QD” NCT00557401 ↗ |
| Modality | Small molecule | — CHEMBL2107312 ↗ |
| Route | Oral | “XP19986 Sustained Release (SR) 20 mg tablet taken orally” NCT00557401 ↗ |